UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) | December 4, 2017 |
ENCISION, INC. |
(Exact name of registrant as specified in its charter) |
Colorado | 0-28604 | 84-1162056 |
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
6797 Winchester Circle, Boulder, Colorado | 80301 |
(Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code | (303) 444-2600 |
|
(Former name or former address, if changed since last report.) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 9.01 | Financial Statements and Exhibits. |
(d) | Exhibits. |
99.1 | Press Release issued by ENCISION, INC., December 4, 2017 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ENCISION, INC. | |
(Registrant) | |
Date December 4, 2017 | |
/s/ Mala M Ray | |
Mala M Ray | |
Controller | |
Principal Accounting Officer |
Encision Announces Death of VP-Product Development Officer Michael Biggs
BOULDER, Colo., Dec. 4, 2017 /PRNewswire/ -- Encision Inc. (OTC:ECIA) announced today that Michael Biggs, 48, its VP of Product Development died from injuries incurred from a bicycle accident.
Mr. Biggs was employed with Encision for five years and was promoted to the VP position in 2014. He held a B.S. degree from the University of California and an M.B.A. degree from the University of Colorado, and was a named inventor on over two dozen U.S. patents in the medical device field. To maintain continuity in the oversight of the VP-Product Development's functions, Dave Newton, our VP-Technology, will oversee the activities of product development.
"Our hearts are heavy with the loss of Mike Biggs," said Greg Trudel, President and CEO of Encision. "He was a brilliant colleague and a key contributor to our leadership team. Mike's passions and insights on medical devices helped Encision to deliver a cutting edge portfolio of products and his vision and contributions will enable Encision to continue to drive new levels of patient safety in laparoscopy. Our thoughts and prayers are with Mike's wife, children and family."
Encision Inc. designs and markets a portfolio of high performance surgical instrumentation that delivers advances in patient safety with AEM technology, surgical performance, and value to hospitals across a broad range of minimally invasive surgical procedures. Based in Boulder, Colorado, the company pioneered the development and deployment of Active Electrode Monitoring, AEM technology, to eliminate dangerous stray energy burns during minimally invasive procedures. For additional information about all our products, please visit www.encision.com.
In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the Company notes that statements in this press release and elsewhere that look forward in time, which include everything other than historical information, involve risks and uncertainties that may cause actual results to differ materially from those indicated by the forward-looking statements. Factors that could cause the Company's actual results to differ materially include, among others, its ability to develop new or enhanced products and have such products accepted in the market, its ability to increase net sales through the Company's distribution channels, its ability to compete successfully against other manufacturers of surgical instruments, insufficient quantity of new account conversions, insufficient cash to fund operations, delay in developing new products and receiving FDA approval for such new products and other factors discussed in the Company's filings with the Securities and Exchange Commission. Readers are encouraged to review the risk factors and other disclosures appearing in the Company's Annual Report on Form 10-K for the year ended March 31, 2017 and subsequent filings with the Securities and Exchange Commission. We do not undertake any obligation to update publicly any forward-looking statements, whether as a result of the receipt of new information, future events, or otherwise.
CONTACT: Mala Ray, Encision Inc., 303-444-2600, mray@encision.com